Introduction {#s1}
============

Zn^2+^, as a structural and catalytic cofactor, plays crucial roles in regulating protein functions, and thereby is essential for many cellular processes, including cell development and immunological functions ([@bib22]). Not surprisingly, Zn^2+^ deficiency can lead to a variety of disabling human diseases, such as diabetes, cancer and Alzheimer's disease ([@bib30]). In humans, the intracellular level of zinc is tightly regulated by two major Zn^2+^ transporter families, the SLC39 (ZIPs) family and the SLC30 (ZnTs) family ([@bib11]). ZIPs mediate the Zn^2+^ uptake either from the extracellular space or organelle into cytosolic space, whereas ZnTs transport Zn^2+^ in the opposite direction. ZnT8, one of the 10 ZnTs that have been identified so far ([@bib5]), is localized in the insulin secretory granules of pancreatic β cells and responsible for the accumulation of high level of zinc inside granules, which is required for the packing of insulin in the hexameric form ([@bib10]). ZnT8 knock-out in mice leads to severe defects in insulin processing, storage and secretion as well as glucose tolerance, indicating its critical role in β-cell function and glucose metabolism ([@bib29]; [@bib36]). Indeed, the aberrant function of ZnT8 is linked to both type 1 and 2 diabetes ([@bib3]). ZnT8 has been shown to be one of the major autoantigens in type 1 diabetes ([@bib35]), and autoantibodies against ZnT8 (ZnT8A) can be detected in \~70% of young patients with type 1 diabetes ([@bib17]). In addition, an R325W mutation of ZnT8 has been shown to increase the risk of type 2 diabetes ([@bib31]; [@bib34]). On the other hand, in a 2014 study, researchers also identified 12 rare loss-of-function mutations caused by truncation in ZnT8 that can lead to a 65% reduction in the risk of type 2 diabetes ([@bib13]). Therefore, ZnT8 has become an important target for diagnosis, prevention or intervention of both of type 1 and 2 diabetes.

ZnT8 functions as a Zn^2+^/H^+^ exchanger ([@bib26]; [@bib32]). Despite of extensive biochemical and physiological studies of ZnT8, our understanding of its Zn^2+^/H^+^ exchange mechanism is hindered by the lack of high-resolution structures of ZnT8 in different transporting states. To date, the structures of YiiP, a bacterial member of SLC30 family that is distantly related to human ZnT8 with 14% sequence identity ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), have been determined by X-ray crystallography and cryo-electron microscopy (cryo-EM) ([@bib8]; [@bib19]; [@bib20]; [@bib21]), and these structures have been used as the model for ZnT8. The crystal structure of *Escherichia coli* YiiP (EcYiiP) was determined in an outward-facing conformation at 2.9 Å resolution and the transporter forms a 'V'-shaped homodimer, with each subunit consisting of a transmembrane domain (TMD) with six membrane-spanning helices and a cytosolic C-terminal domain (CTD) ([@bib20]; [@bib21]). Distinct from the crystal structure of EcYiiP, the cryo-EM structure of *Shewanella oneidensis* YiiP (SoYiiP) was determined in an inward-facing conformation at 4.1 Å resolution ([@bib8]; [@bib19]). Comparison of the two structures reveals major conformational changes in the TMD. Since the two structures of YiiP were determined by different methods with the proteins stabilized in different chemical environments (lipid vs detergent), it is unclear whether the observed structural differences truly reflect the conformational changes upon Zn^2+^ transport. In light of their low-sequence similarity ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), it is also unclear whether human ZnT8 (HsZnT8) shares the same Zn^2+^ transport mechanism as bacterial YiiP. Here, we determine the cryo-EM structures of HsZnT8 in both outward (luminal)- and inward (cytosolic)-facing states. These structures reveal a large number of novel features in HsZnT8 that are distinct from bacterial YiiP. Structural comparison between the two states elucidates the conformational rearrangements at the TMD of each ZnT8 subunit during Zn^2+^ transport cycle. Our structural results, together with mutagenesis and cell based functional assays, illustrate a plausible Zn^2+^/H^+^ exchange mechanism in ZnT8 and also provide a structure platform for diabetes drug development targeting HsZnT8.

Results {#s2}
=======

Structure determination of HsZnT8 {#s2-1}
---------------------------------

HsZnT8 isoform B lacking the N-terminal 49 residues gave higher protein expression than the full-length isoform A and was used for structure determination in this study ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}). To be consistent with the amino acid numbering used for isoform A in other studies, the starting residue of isoform B is numbered as 50 in the subsequent description of our structural and functional analyses. The purified HsZnT8 in digitonin detergent formed a dimer in solution and eluted as a monodisperse peak on size exclusion chromatography ([Figure 1---figure supplement 2b](#fig1s2){ref-type="fig"}). The small size of HsZnT8 (about 70 kDa as a dimer) imposed a high technical challenge for its structure determination using cryo-EM. Volta phase plate was employed in data collection to enhance the contrast for better image alignment ([@bib9]), and the initial data was collected using the wild-type HsZnT8 (HsZnT8-WT) sample prepared in the presence of Zn^2+^ (1 mM). The single particle reconstruction yielded a map of the transporter in an outward-facing conformation, but the overall resolution of 4.1 Å is insufficient for accurate model building ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Subsequently, we introduced two mutations, D110N and D224N, at the predicted primary Zn^2+^ binding site within the TMD of HsZnT8 (HsZnT8-DM) ([@bib16]). As the primary site functions as the transfer center for Zn^2+^ transport, we reasoned that by abolishing its Zn^2+^-binding capability, the HsZnT8-DM mutant could potentially stabilize the transporter in a specific state. Indeed, the double mutations appeared to further stabilize the transporter in outward-facing conformation and data collected using HsZnT8-DM sample prepared in the absence of Zn^2+^ yielded a map of the outward-facing transporter with an improved resolution (\~3.8 Å) as compared to HsZnT8-WT, allowing us to build a near complete model containing 302 out of 320 residues for each subunit, with the help of the crystal structure of EcYiiP ([@bib20]; [Figure 1---figure supplements 3](#fig1s3){ref-type="fig"}, [4a](#fig1s4){ref-type="fig"}).

Interestingly, the EM data collected with HsZnT8-WT in the absence of Zn^2+^ yielded a structure of the dimeric transporter with heterogeneous conformations- one subunit in an inward-facing and the other in an outward-facing conformation ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Similar heterogeneous conformations have been observed in other multimeric transporters, such as nucleoside ([@bib15]) and glutamate transporters ([@bib2]). Albeit the cryo-EM structure of HsZnT8-WT in the absence of Zn^2+^ was determined at a low overall resolution (5.9 Å), the secondary structure features were well resolved for both TMD and CTD, enabling us to build a relatively accurate model for the inward-facing subunit by rigid-body fitting of the individual transmembrane helix and CTD from the outward-facing structure into the map ([Figure 3---figure supplement 1g](#fig3s1){ref-type="fig"}). Furthermore, the density for most of the linkers between adjacent transmembrane helices were well defined in the cryo-EM map, further facilitating the model building of the inward-facing structure ([Figure 3---figure supplement 1g](#fig3s1){ref-type="fig"}).

Overall structure of HsZnT8 in the outward-facing conformation {#s2-2}
--------------------------------------------------------------

The structure of HsZnT8 in the outward-facing state shows a 'V'-shaped dimeric architecture similar to the crystal structure of EcYiiP, with the two TMDs forming the branches, whereas the two tightly packed CTDs located at the base of the 'V' and mediating the majority of the dimerization interactions ([Figure 1a--c](#fig1){ref-type="fig"}, [Figure 1---figure supplement 5a](#fig1s5){ref-type="fig"}). The gap between the two TMDs in the HsZnT8 dimer is narrower than that of EcYiiP ([Figure 1---figure supplement 5b](#fig1s5){ref-type="fig"}).

![Overall structure of HsZnT8-DM in the outward-facing conformation.\
(**a**) Cryo-EM reconstruction of HsZnT8-DM in the outward-facing conformation (contour level: 0.018, 4.8 σ). The two subunits are colored in blue and green, respectively. (**b**) The ribbon representation of the HsZnT8-DM dimer in the side view. (**c**) The cylinder representation of the HsZnT8-DM dimer in the top view with TMs from one subunit labeled. (**d**) The ribbon representation of a single HsZnT8-DM subunit with secondary structural elements labeled. (**e**) Zoomed-in views of the interface between the two adjacent CTDs in two orthogonal orientations. (**f**) Zoomed-in view of the interface between the two adjacent TMDs.](elife-58823-fig1){#fig1}

The CTD of HsZnT8 adopts a αββαβ fold, a conserved feature of SLC30 family ([Figure 1d](#fig1){ref-type="fig"}, [Figure 1---figure supplements 2a](#fig1s2){ref-type="fig"}, [6](#fig1s6){ref-type="fig"}). While one face of the three-stranded β sheet is covered by the two α helices, the other face of the β sheet provides the major contact surface for the dimerization interactions with its counterpart from the neighboring CTD ([Figure 1e](#fig1){ref-type="fig"}). The protein contacts at the core of this dimer interface are mainly hydrophobic, consisting of multiple aromatic residues including Trp306s, His304s and Phe134s ([Figure 1e](#fig1){ref-type="fig"}). Notably, Phe134 comes from the extended loop between TM2 and TM3 of TMD, which protrudes into the CTD of the neighboring subunit and tucks into the pocket between β1 and the C-terminal tail. The CTD dimerization also involves multiple hydrogen bonding interactions, for example the H-bonds between Arg331s and Gln350s ([Figure 1e](#fig1){ref-type="fig"}).

Arg325, whose mutation (R325W) is associated with higher risk of type 2 diabetes, is located in a short loop (residues 321--327) between β2 and α2 of CTD. This loop has also been proposed to be the antigen epitope for autoantibodies from type 1 diabetes patients. Structurally, the two epitope loops in HsZnT8 dimer are physically separated from each other and completely exposed to the cytosolic solution at the distal tip of CTD, providing ample space for antibody access ([Figure 1e](#fig1){ref-type="fig"}). On the contrary, the two equivalent loops in EcYiiP dimer are tightly packed with each other and contribute to part of the dimerization contact ([Figure 1---figure supplement 5d](#fig1s5){ref-type="fig"}). As the epitope loop is remote from the Zn^2+^ transport pathway, it is unclear how R325W mutation and the binding of autoantibodies to this loop affect the transporter function.

Among the six transmembrane helices (TM1-TM6) in the TMD of each HsZnT8 subunit, TMs 3 and 6 also participate in the dimerization through hydrophobic interactions with their counter parts from the neighboring subunit at the cytosolic leaflet of the membrane ([Figure 1f](#fig1){ref-type="fig"}). In addition, Arg138s at the N-terminal ends of TM3s and Glu276s at the C-terminal ends of TM6s from both subunits converge at the cytosolic surface of the membrane and form a cluster of salt bridges ([Figure 1e](#fig1){ref-type="fig"}). The extensive dimerization interactions at CTDs as well as TMs 3 and 6 imply that these parts of the protein likely remain static during Zn^2+^ transport cycle, leaving other part of the TMD (TMs 1, 2, 4 and 5) undergo conformational changes as will be further discussed later.

Zn^2+^ binding sites in CTD {#s2-3}
---------------------------

The structure of HsZnT8-DM reveals two adjacent Zn^2+^ binding sites (designated as S~CD1~ and S~CD2~) within each CTD, in a pocket encircled by the U-shaped loop near the C-terminus of the protein right after β3 ([Figure 2a--c](#fig2){ref-type="fig"}). The EM map shows strong density peaks at both S~CD1~ and S~CD2~ that can be assigned to Zn^2+^ ions ([Figure 2b,c](#fig2){ref-type="fig"}). Although Zn^2+^ binding was also observed in the CTD of EcYiiP, the exact locations and the surrounding chemical environments of S~CD1~ and S~CD2~ in HsZnT8 are distinct from those in EcYiiP ([Figure 1---figure supplement 5d](#fig1s5){ref-type="fig"}). In HsZnT8, Zn^2+^ ions in both S~CD1~ and S~CD2~ are coordinated in a classical tetrahedral geometry with the S~CD1~ Zn^2+^ chelated by His52, His54, Cys361, and Cys364, and the S~CD2~ Zn^2+^ chelated by Cys53, His301, His318 and Glu352 ([Figure 2b,c](#fig2){ref-type="fig"}). Consistent with our model, Cys361 and Cys364 at the C-terminus of ZnT8 have been predicted, based on sequence alignment, to be important for zinc binding ([@bib27]). Notably, His52, Cys53 and His54 come from the HCH (His52-Cys53-His54) motif at the N-terminus of the neighboring HsZnT8 subunit. The HCH motif seals off S~CD1~ and S~CD2~, making the two bound Zn^2+^ ions buried in the protein. As the HsZnT8-DM sample was prepared in the absence of Zn^2+^, the bound Zn^2+^ ions likely come from the host cells for protein expression and appear to be integral part of the protein with high-affinity binding. The HCH motif is highly conserved in ZnT8s ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}) as well as some subfamilies of ZnT, but is not present in YiiP transporter whose N-terminus does not participate in Zn^2+^ binding ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). As a result, the two CTD Zn^2+^ ions in YiiP are partially solvent-exposed with water molecules participating in the ion coordination ([@bib20]).

![The Zn^2+^ binding sites in HsZnT8.\
(**a**) Overall view of Zn^2+^ binding sites in HsZnT8-WT. The location of each site is indicated by a dash box. (**b**) and (**c**) Detailed views of S~CD1~ and S~CD2~ in the structure of HsZnT8-DM in the absence of Zn^2+^. The cryo-EM densities are displayed as blue mesh (6 σ). (**d**) , (**e**) and (**f**) Detailed views of S~IF~ and S~TM~ in the structures of HsZnT8-DM in the absence of Zn^2+^ and HsZnT8-WT in the presence of Zn^2+^. The cryo-EM densities are displayed as blue mesh (6 σ). The density differences between the cryo-EM maps of HsZnT8-DM in the absence of Zn^2+^ and HsZnT8-WT in the presence of Zn^2+^ are shown as orange blobs (8 σ). (**g**) Representative fluorescence traces of vesicular Zn^2+^ uptake for the cells expressing wild-type HsZnT8 or its mutants. Non-induced HEK293F cells (empty) was used as the negative control. Expression levels of HsZnT8 wild type and mutants were monitored by western blot using anti-flag antibody. Mouse anti-β-actin was used as a loading control. (**h**) Relative Zn^2+^ uptake rate between HsZnT8 and its mutants (Mean ± SD). The uptake rates were normalized to the expression levels of HsZnT8. Each experiment was repeated four times. Significance calculated using two-tailed students t-test; between wild-type and mutants; \*\*\*p\<0.001.\
Figure 2---source data 1.Source data for [Figure 2g](#fig2){ref-type="fig"}.\
Figure 2---source data 2.Source data for [Figure 2h](#fig2){ref-type="fig"}.](elife-58823-fig2){#fig2}

The HCH motif is connected to the N-terminus of TM1 by a short 7-residue linker whose density is clearly visible in the low-pass filtered cryo-EM map ([Figure 1---figure supplement 4b](#fig1s4){ref-type="fig"}), but cannot be modeled due to the lack of side-chain densities. The Zn^2+^-mediated tight tethering between HCH motif and the neighboring CTD likely imposes constrain to the position and movement of TM1 ([Figures 1b](#fig1){ref-type="fig"} and [2a](#fig2){ref-type="fig"}). It is, therefore, appealing to speculate that the Zn^2+^-mediated stretching and tethering of the N-terminal segment of HsZnT8 that immediately precedes TM1 may play a critical role in the stability and transport function of the TMD in HsZnT8. To test this hypothesis, we generated an N-terminal deletion mutation lacking the HCH motif (ΔHCH) and tested the mutant function using a cell-based Zn^2+^ uptake assay. With comparable protein expression level, cells expressing ΔHCH mutant showed marked reduction in Zn^2+^ uptake activity as compared to cells expressing wild-type transporter ([Figure 2g,h](#fig2){ref-type="fig"}), confirming the functional importance of the HCH motif.

From the structure of HsZnT8-WT determined in the presence of Zn^2+^, we also observed cryo-EM density from a third Zn^2+^ ion coordinated by His137 and His345 at the interface between CTD and TMD, which is designated as S~IF~ ([Figure 2a,d](#fig2){ref-type="fig"}). This Zn^2+^ density was not present in the HsZnT8-DM structure which was determined in the absence Zn^2+^ ([Figure 2d](#fig2){ref-type="fig"}), suggesting a lower affinity Zn^2+^ binding at S~IF~ as compared to the other two CTD sites (S~CD1~ and S~CD2~). Interestingly, S~IF~ is positioned right at the cytosolic entrance to the Zn^2+^ transport pathway ([Figure 2a](#fig2){ref-type="fig"}) and mutation of the two S~IF~ histidines resulted in marked reduction in Zn^2+^ transport rate ([Figure 2g,h](#fig2){ref-type="fig"}). As the physiological function of ZnT8 is to transport Zn^2+^ ions from low concentration cytosol (free Zn^2+^ concentration:\~1 nM) to high concentration granule (free Zn^2+^ concentration:\~120 nM) ([@bib18]; [@bib14]), we suspect S~IF~ can help trap Zn^2+^ ions and effectively increase the local Zn^2+^ concentration, which in turn facilitate the ion transport against over 100-fold concentration gradient.

Zn^2+^ binding sites in TMD {#s2-4}
---------------------------

The primary Zn^2+^ binding site in HsZnT8 TMD (designated as S~TM~) is highly conserved in SLC30 family ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). S~TM~ is surrounded by His106, Asp110, His220 and Asp224 at the middle of the membrane and exposed to the luminal solution in the outward-facing structure ([Figure 2e](#fig2){ref-type="fig"}). The density of a bound Zn^2+^ can be defined in the EM map of HsZnT8-WT ([Figure 2f](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Although the side-chains of those ligand residues are not well defined in the map due to the resolution limit, their locations and conservation likely point to a classical tetrahedral coordination as observed in EcYiiP structure. As expected, S~TM~ is vacant in HsZnT8-DM structure because the two Zn^2+^-coordinating acidic residues (Asp110 and Asp224) were replaced with asparagines in the mutant and the sample was also prepared in the absence of Zn^2+^ ([Figure 2e](#fig2){ref-type="fig"}). Although the structure of HsZnT8-DM is virtually identical to that of HsZnT8-WT ([Figure 2---figure supplement 1e](#fig2s1){ref-type="fig"}), the mutant has almost no Zn^2+^ transport activity ([Figure 2g,h](#fig2){ref-type="fig"}), confirming the central role of S~TM~ to HsZnT8 function.

Structural changes from outward- to inward-facing states {#s2-5}
--------------------------------------------------------

Intriguingly, the two subunits in the cryo-EM structure of HsZnT8-WT obtained in the absence of Zn^2+^ adopt different conformations, with one subunit in inward-facing but the other in outward-facing conformation ([Figure 3a](#fig3){ref-type="fig"}). Although at lower resolution, the secondary structure features from almost all part of the inward-facing subunit can be well defined, allowing us to visualize the structural changes between inward and outward-facing conformations ([Figure 3a,b](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In the outward-facing conformation, TMs 1--5 are tightly bundled at the cytosolic half of TMD, occluding the space between S~TM~ and the cytosol; at the luminal half of TMD, TMs 2--6 enclose a deep cavity, penetrating into the central S~TM~ where Zn^2+^ binds and providing a solvent accessible passageway from luminal side ([Figure 2a](#fig2){ref-type="fig"}, [Figure 3c](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2d](#fig3s2){ref-type="fig"}). In the inward-facing conformation, TMs 2--6 are tightly bundled at the luminal half of TMD and occlude the solvent accessible passageway from luminal side; TMs 1--6 enclose a wide open cavity at the cytosolic half of TMD, making S~TM~ readily accessible from cytosol ([Figure 3a--c](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2d](#fig3s2){ref-type="fig"}).

![Structural transitions between outward- and inward-facing conformations.\
(**a**) 3D reconstruction of HsZnT8-WT in the absence of Zn^2+^ and the ribbon representation of the model fitted into cryo-EM map. (**b**) Top view of the TMD (TMs 1--6) from the inward-facing subunit in ribbon representation fitted into cryo-EM map. (**c**) The surface-rendered models of an outward-facing subunit from the HsZnT8-DM structure (left) and an inward-facing subunit from the HsZnT8-WT structure obtained in the absence of Zn^2+^ (right). The brown dashed lines indicate the opening of S~TM~ to either the luminal or the cytosolic side. (**d**) Superposition between the structures of HsZnT8-DM dimer (grey) and HsZnT8-WT dimer (orange) both obtained in the absence of Zn^2+^ (**e**) Superposition of the TMD structures between the outward-facing subunit from HsZnT8-DM (with TMs colored in grey) and the inward-facing subunit from HsZnT8-WT (with TMs 1--2 colored in brown, TMs 4--5 in green and TMs 3 and six in blue), revealing two different types of rocking motions (indicated by the arrows).](elife-58823-fig3){#fig3}

Significant scissors-like rotation between two TMDs of bacterial YiiP dimer was observed between outward- and inward-facing conformations ([@bib19]). Consequently, the relative position between the two TM3 helices changes significantly between the two conformations ([Figure 1---figure supplement 5a](#fig1s5){ref-type="fig"}, [Figure 3---figure supplement 3b](#fig3s3){ref-type="fig"}). In sharp contrast, the regions that participate in dimerization of HsZnT8, including CTD, TM3 and TM6, can all be well superimposed between the structures of inward and outward-facing conformations, indicating that these regions remain static during Zn^2+^ transport cycle ([Figure 3d,e](#fig3){ref-type="fig"}). However, large structural rearrangements occur among TMs 1, 2, 4 and 5 of HsZnT8, resulting from two different types of rocking motions ([Figure 3e](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2a--c](#fig3s2){ref-type="fig"}, [Video 1](#video1){ref-type="video"}). From outward to inward-facing conformation, TMs 4 and 5, as a bundle, swing away from TMs 3 and 6, using their luminal ends as the pivot point; TM5 tilts approximately 35° from the center of TMD to the peripheral, resulting in the opening of cytosolic ion pathway ([Figure 3e](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2a--c](#fig3s2){ref-type="fig"}, [Video 1](#video1){ref-type="video"}). TMs 1 and 2, as another bundle, undergo large inward rotation hinged at the cytosolic end of TM2, occluding the luminal ion pathway ([Figure 3e](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2a--c](#fig3s2){ref-type="fig"}, [Video 1](#video1){ref-type="video"}).

###### Structural transitions of the TMD of HsZnT8 between outward- and inward-facing conformations.

In addition, we superimposed the TMD regions between the inward-facing structures of HsZnT8 and SoYiiP. This comparison revealed no major structural differences for most of TMs between HsZnT8 and SoYiiP, with the exception of TM1 ([Figure 3---figure supplement 3d,e](#fig3s3){ref-type="fig"}). In the inward-facing conformation of HsZnT8, TM1 packs tightly against TM2 in a manner similar to that in the outward-facing conformation. TM1 of SoYiiP, however, rotates away from TM2 during the transition from outward- to inward-facing states ([Figure 3---figure supplement 3d](#fig3s3){ref-type="fig"}). As mentioned above, the tethering of the N-terminal segment of HsZnT8 to CTD may restrain the flexibility of TM1 and limit its rocking rotation upon conformational change. This explains why the TM1s of HsZnT8 and SoYiiP undergo different types of structural changes during the transport cycle. We also noticed that, HsZnT8 adopts a more open inward-facing conformation as compared to SoYiiP, due to the altered position of TM1 ([Figure 3---figure supplements 2d](#fig3s2){ref-type="fig"}, [3d](#fig3s3){ref-type="fig"}). It is tempting to speculate that, the wide open cytosolic cavity in the inward-facing conformation of HsZnT8 could facilitate the fast diffusion of Zn^2+^ from the cytosol to the primary Zn^2+^ site in TMD and thereby may increase the efficiency of Zn^2+^ uptake into insulin granule.

The mechanism for Zn^2+^/H^+^ antiport in HsZnT8 {#s2-6}
------------------------------------------------

The conformational heterogeneity of HsZnT8-WT in the absence of Zn^2+^ along with small size of the protein likely causes difficulty in obtaining a high-resolution cryo-EM structure. However, the observation of different conformations between the two subunits within each HsZnT8-WT dimer implies that the Zn^2+^ transport activity of HsZnT8 is unlikely to be coupled between the two subunits within a dimer, allowing each subunit to carry out Zn^2+^ transport activity independently ([Figure 4a](#fig4){ref-type="fig"}). No occluded state has been observed in all of our structural analysis, leading us to suggest a simple two-state model for Zn^2+^ transport function of HsZnT8 ([Figure 4b](#fig4){ref-type="fig"}). Each transporter subunit may simply shuttle between inward- and outward-facing states with S~TM~ housing the Zn^2+^ ion in a pH-dependent manner. At inward-facing state, higher cytosolic pH environment allows for high-affinity Zn^2+^ binding at S~TM~. The presence of a secondary Zn^2+^ site at the cytosolic entrance of the ion pathway may help increase the local Zn^2+^ concentration and facilitate the Zn^2+^ occupancy at S~TM~ even at low concentration. Upon moving to the outward-facing state, S~TM~ becomes exposed to the low pH environment of the insulin secretory granule and the subsequent protonation of S~TM~, likely through the two histidines, effectively reduce the Zn^2+^ affinity and promote its release ([Figure 4b](#fig4){ref-type="fig"}). The transporter would then move back to inward-facing states where the apo S~TM~ gets deprotonated at higher pH and ready for the next transport cycle ([Figure 4b](#fig4){ref-type="fig"}). Thus, the direction and efficiency of Zn^2+^ transport are simply determined by the pH and Zn^2+^ concentrations on both sides of the transporter.

![Proposed working model of HsZnT8.\
(**a**) A cartoon representation illustrates that each ZnT8 subunit may shuttle between inward- and outward-facing conformations independently during the Zn^2+^ transport cycle. (**b**) Schematic representation of a simplified model for the transport cycle of ZnT8. For simplicity, both subunits in a ZnT8 dimer are drawn in homogeneous conformations, but they likely carry out Zn^2+^/H^+^ exchange function independent from each other, as shown in **a**.](elife-58823-fig4){#fig4}

Discussion {#s3}
==========

In this work, we determined the first cryo-EM structures of HsZnT8 in both outward- and inward-facing conformations. Our structural and functional analyses reveal a total of 4 Zn^2+^ binding sites in each subunit, including one primary site in the TMD (S~TM~), one site at the interface between TMD and CTD (S~IF~), and two adjacent sites located in an open pocket of CTD covered by a HCH motif from the N-terminal segment of neighboring subunit (S~CD1~ and S~CD2~). The primary Zn^2+^ binding site in the TMD of ZnT8 consists of His-Asp-His-Asp residues, with one residue difference as compared to Asp-Asp-His-Asp of YiiP. It has been shown that the replacement of Asp to His in the primary site of ZnTs significantly increases the specificity of Zn^2+^ binding ([@bib16]). We proposed that the weak binding of Zn^2+^ to the interfacial site S~IF~ in HsZnT8 may help to increase local Zn^2+^ concentration at the entrance of cytosolic ion pathway, which could facilitate the recruitment of cytosolic Zn^2+^ to the primary site in TMD. Indeed, our cell based uptake assay showed that disruption of S~IF~ markedly reduced the transport activity of HsZnT8. This interfacial Zn^2+^ binding site is not present in YiiP.

The two adjacent Zn^2+^ binding sites in CTD, S~CD1~ and S~CD2~, are localized in a similar position between ZnT8 and YiiP, but are formed by very different structural elements. In HsZnT8, S~CD1~ and S~CD2~ is surrounded by the β-sheet and C-terminal tail of CTD from one subunit and the N-terminal segment from the other. Therefore, the binding of Zn^2+^ to S~CD1~ and S~CD2~ in HsZnT8 will anchor each CTD to the TMD of the neighboring subunit. In contrast, both of C-terminal tail of CTD and N-terminal segment are not involved in the formation of S~CD1~ and S~CD2~ in YiiP. Instead, S~CD1~ and S~CD2~ of YiiP is sandwiched between two neighboring CTDs, such that the binding of Zn^2+^ to S~CD1~ and S~CD2~ plays an important role in the dimerization of CTD in YiiP.

A comparison of our outward- and inward-facing structures of HsZnT8 reveals detailed structural rearrangements within each TMD during the transport cycle. Importantly, the motions observed during the transition from outward- to inward-facing states are significantly different between ZnT8 and YiiP ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Firstly, different from YiiP, no inter-TMDs rotation occurs during the transport cycle of ZnT8. The positions of TM3 and 6 of HsZnT8 remain unchanged between outward- and inward-facing states. Secondly, due to the tethering of HCH motif in the N-terminal segment to CTD, the movement of TM1 of HsZnT8 is largely restricted. As a result, TM1 of HsZnT8 undergoes distinct structural rearrangement between outward- and inward-facing states, as compared to that of YiiP, leading to a wider opening of cytosolic cavity in the inward conformation, which might be important for the efficient diffusion of Zn^2+^ from the cytosol to the primary Zn^2+^ binding site in TMD. This observation partially explains why the HCH motif is critical for the transport activity of HsZnT8. Notably, mutation of a single residue in the HCH motif of ZnT2 (H54R) was directly linked with transient neonatal zinc deficiency (TNZD), further indicating the significance of this motif in the function of SLC30 family of zinc transporter ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}; [@bib7]). It also worth noting that similar HCH motif has been found in the C-terminus of copper importer Ctr1 that can bind Cu^2+^ and is important for the regulation of Ctr1 activity ([@bib23]).

In conclusion, our structural and functional analyses provide a wealth of information for defining the Zn^2+^/H^+^ antiporter mechanism of HsZnT8. Additionally, our detailed structural model of HsZnT8 presented here provide a basis for understanding a number of mutations in ZnT8 that are associated with diabetes ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), and may serve as the template for homologous modeling of other members in SLC30 family.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                                Source or reference                                                            Identifiers                                                                                                                                                                   Additional information
  (species) or resource                                                                                                                                                                                                                                                                                                                                    
  ------------------------------------------------ ------------------------------------------ ------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  Strain, strain background (*Escherichia coli*)   TOP10                                      Thermo Fisher Scientific                                                       Cat\# 18258012                                                                                                                                                                

  Strain, strain background (*Escherichia coli*)   DH10bac                                    Thermo Fisher Scientific                                                       Cat\# 10361012                                                                                                                                                                

  Cell line (*Spodoptera frugiperda*)              Sf9 cells                                  Thermo Fisher Scientific                                                       Cat\# 11496015; RRID:[CVCL_0549](https://scicrunch.org/resolver/CVCL_0549)                                                                                                    

  Cell line (*Homo sapiens*)                       FreeStyle 293 F cells                      Thermo Fisher Scientific                                                       Cat\# R79007; RRID:[CVCL_D603](https://scicrunch.org/resolver/CVCL_D603)                                                                                                      

  Recombinant DNA reagent                          pEZT-BM                                    DOI:[10.1016/j.str.2016.03.004](http://dx.doi.org/10.1016/j.str.2016.03.004)   Addgene:74099                                                                                                                                                                 

  Transfected construct (*Homo-sapiens*)           pEZT-BM-ZNT8-N~Flag~and mutations          This paper                                                                     N/A                                                                                                                                                                           transfected construct (human)

  Antibody                                         Mouse monoclonal anti-FLAG tag             Sigma                                                                          Cat\# F1804                                                                                                                                                                   WB (1:5000)

  Antibody                                         Mouse monoclonal anti-b-actin              Santa Cruz Biotechnology                                                       Cat\# sc-69879; RRID:[AB_1119529](https://scicrunch.org/resolver/AB_1119529)                                                                                                  WB (1:200)

  Antibody                                         Mouse IgG HRP linked whole Ab              GE healthcare                                                                  Cat\# NA931V; RRID:[AB_772210](https://scicrunch.org/resolver/AB_772210)                                                                                                      WB (1:10000)

  Chemical compound, drug                          Sodium Butyrate                            Sigma-Aldrich                                                                  Cat\# 303410                                                                                                                                                                  

  Chemical compound, drug                          n-Dodecyl-b-Maltopyranoside                Anatrace                                                                       Cat\# D310, D310s                                                                                                                                                             

  Chemical compound, drug                          Cholesteryl hemisuccinate                  Sigma-Aldrich                                                                  Cat\# C6512                                                                                                                                                                   

  Chemical compound, drug                          Lauryl Maltose Neopentyl Glycol            Anatrace                                                                       Cat\# NG310                                                                                                                                                                   

  Chemical compound, drug                          Digitonin                                  Sigma                                                                          Cat\# D141                                                                                                                                                                    

  Chemical compound, drug                          1,10-Phenanthroline                        Sigma                                                                          Cat\# 131377                                                                                                                                                                  

  Chemical compound, drug                          FluoZin−3                                  Thermo Fisher Scientific                                                       Cat\# F24194                                                                                                                                                                  

  Peptide, recombinant protein                     3X FLAG Peptide                            Sigma                                                                          Cat\# F4799                                                                                                                                                                   

  Software, algorithm                              MotionCor2                                 [@bib38]                                                                       <https://emcore.ucsf.edu/ucsf-software>                                                                                                                                       

  Software, algorithm                              GCTF                                       [@bib37]                                                                       <https://www2.mrc-lmb.cam.ac.uk/research/locally-developed-software/zhang-software/#gctf>                                                                                     

  Software, algorithm                              RELION                                     Scheres, 2012                                                                  <http://www2.mrc-lmb.cam.ac.uk/relion>                                                                                                                                        

  Software, algorithm                              Chimera                                    [@bib28]                                                                       <https://www.cgl.ucsf.edu/chimera>; RRID:[SCR_004097](https://scicrunch.org/resolver/SCR_004097)                                                                              

  Software, algorithm                              PyMol                                      Schrödinger                                                                    <https://pymol.org/2>; RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)                                                                                           

  Software, algorithm                              COOT                                       [@bib12]                                                                       [https://www2.mrc-lmb.cam.ac.uk/ personal/pemsley/coot](https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot); RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)   

  Software, algorithm                              PHENIX                                     [@bib1]                                                                        <https://www.phenix-online.org>                                                                                                                                               

  Software, algorithm                              GraphPad Prism                             GraphPad Software                                                              <https://www.graphpad.com/scientific-software/prism>                                                                                                                          

  Software, algorithm                              OriginPro 8                                OriginLab Corp.                                                                <https://www.originlab.com>                                                                                                                                                   

  Other                                            Superose 6 Increase10/300 GL               GE Healthcare                                                                  Cat\# 29091596                                                                                                                                                                

  Other                                            Anti-DYKDDDDK G1 Affinity Resin            GeneScript                                                                     Cat\# 10362101                                                                                                                                                                

  Other                                            Amicon Ultra-15 Centrifugal Filter Units   Milliporesigma                                                                 Cat\# UFC9100                                                                                                                                                                 

  Other                                            Quantifoil R 1.2/1.3 grid Au300            quantifoil                                                                     Cat\# Q37572                                                                                                                                                                  

  Other                                            Cellfectin                                 Invitrogen                                                                     Cat\# 10362100                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein expression and purification {#s4-1}
-----------------------------------

Human ZnT8 cDNA (residues 50--369) was cloned into pEZT vector with an N-terminal Flag tag and heterologously expressed in HEK293F cells (R79007, Thermo Fisher Scientific) using the BacMam system. The baculovirus generated in Sf9 cells (11496015, Thermo Fisher Scientific) was used to infect HEK293F cells at a ratio of 40:1 (cells:virus, v/v) and 10 mM sodium butyrate were added to the cell culture to boost protein expression. 48 hr after infection at 37°C, cells were collected by centrifugation at 4000 g. All purification procedures were carried out at 4°C unless specified otherwise. The cell pellet was re-suspended in Buffer A (25 mM Hepes pH 7.4, 150 mM NaCl) supplemented with protease inhibitors (1 mg/ml each of DNase, pepstatin, leupeptin, and aprotinin and 1 mM PMSF) and homogenized by sonication on ice. HsZnT8 protein was extracted with 1.5% (w/v) n-dodecyl-β-d-maltopyranoside (DDM; Anatrace) and 0.02% (w/v) cholesteryl hemisuccinate (CHS; Sigma-Aldrich) by gentle agitation for 2 hr. After extraction, the supernatant was collected after centrifugation at 40,000 g and incubated with anti-Flag M2 affinity resin by gentle agitation for 1 hr. Then the resin was collected on a disposable gravity column and washed with 20 column volume of Buffer A supplemented with 0.05% (w/v) lauryl maltose neopentyl glycol (MNG, Anatrace). HsZnT8 was eluted in Buffer A with 0.05% (w/v) MNG and 0.1 mg/ml Flag peptide. The protein eluate was concentrated and further purified by size-exclusion chromatography on a Superose6 10/300 GL column (GE Healthcare) in Buffer A with 0.06% (w/v) Digitonin. The peak fractions were collected and concentrated to 4 mg/ml for grid preparation.

The HsZnT8 D110N/D224N double mutant construct were generated using QuikChange (Agilent). The same procedure was used to express and purify HsZnT8-DM for cryo-EM analysis.

Cryo-EM data collection {#s4-2}
-----------------------

Purified HsZnT8-DM and HsZnT8-WT either in the presence or absence of Zn^2+^ (1 mM) at 4 mg/ml was applied to a glow-discharged Quantifoil R1.2/1.3 300-mesh gold holey carbon grid (Quantifoil, Micro Tools GmbH, Germany), blotted under 100% humidity at 4°C and plunged into liquid ethane using a Mark IV Vitrobot (FEI). Micrographs were acquired on a Titan Krios microscope (FEI) with a K3 Summit direct electron detector (Gatan) in the super-resolution counting mode, operated at 300 kV using the SerialEM software ([@bib24]). The slit width of the GIF-Quantum energy filter was set to 20 eV. A Volta phase plate was used to enhance low-resolution features ([@bib9]). Micrographs were dose-fractioned into 32 frames at the dose rate of \~2 e^−^/Å^2^/frame.

Image processing and 3D reconstruction {#s4-3}
--------------------------------------

Movie frames of HsZnT8-DM micrographs were motion-corrected and binned two-fold, resulting in the pixel size of 0.83 Å, and dose-weighted using the Motioncorr2 program ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}; [@bib38]). CTF correction were performed using the GCTF programs ([@bib37]). The rest of the image processing steps was carried out using RELION 3 ([@bib39]). A few micrographs from the HsZnT8-DM dataset were used for manual picking of \~1000 particles. These particles were subjected to 2D classification. Class averages representing projections of the HsZnT8 dimer in different orientations were used as templates for automated particle picking from the full datasets. A total of 1,287,890 particles were picked from 3384 micrographs. Particles were extracted and binned by four times (leading to 3.32 Å/pixel) and subjected to 2D classification. Particles in good 2D classes were chosen (569,565 in total) for 3D classification using an initial model generated from a subset of the particles in RELION. Particles from the 3D classes showing good secondary structural features were selected and re-extracted into the original pixel size of 0.83 Å. 3D refinements with C2 symmetry imposed resulted in 3D reconstructions to 4 Å resolution. To improve the resolution, we performed another round of 3D classification by using local search in combination with small angular sampling, resulting a new class showing improved density for the entire protein. The final reconstruction was resolved at overall 3.8 Å resolution.

A total of 1,537,280 particles were picked from 3776 micrographs of HsZnT8-WT in the absence of Zn^2+^ ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). 831,115 particles were selected by 2D classification. A map of the ZnT8 in the outward-facing conformation was low-pass filtered and used as the initial reference. The subsequent 3D classification revealed one good class with each ZnT8 subunit adopting a distinct conformation. Therefore, the following 3D refinement was performed with C1 symmetry imposed, leading to a final reconstruction at 5.9 Å resolution.

The same image processing procedure was used to obtain the 3D reconstruction of HsZnT8 in the presence of Zn^2+^, yielding a map at 4.1 Å resolution ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Local resolution was calculated in RELION. Resolution was estimated by applying a soft mask around the protein density with the Fourier Shell Correlation (FSC) 0.143 criterion.

To calculate the difference map, the cryo-EM map of HsZnT8-DM in the absence of Zn^2+^ at 3.8 Å resolution was firstly normalized to the same grey scale as the cryo-EM map of HsZnT8-WT in the presence of Zn^2+^, by using the command 'vop scale' in UCSF Chimera ([@bib28]). After aligning the two maps together in UCSF Chimera, the difference map was calculated by using the command 'vop subtract'.

Model building, refinement and validation {#s4-4}
-----------------------------------------

Density maps of the HsZnT8-DM in the outward-facing conformation was of sufficient quality for de novo model building in Coot ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}; [@bib12]), facilitated by previous crystal structure of EcYiiP (PDB:3H90) ([@bib20]). The model was manually adjusted in Coot and refined against the map by using the real space refinement module with secondary structure and non-crystallographic symmetry restraints in the Phenix package ([@bib1]). The same procedure was used to build the model of HsZnT8-WT in the presence of Zn^2+^.

The density of the HsZnT8-WT in the absence of Zn^2+^ in the inward-facing conformation is relatively poor. The models of CTD and each TM from the outward-facing structure were rigid-body fitted into the cryo-EM density in Coot with good agreement. The model was subsequently refined against the map by using strong secondary structure restraints in Phenix. Model geometries were assessed by using Molprobity as a part of the Phenix validation tools and summarized in [Supplementary file 1](#supp1){ref-type="supplementary-material"} ([@bib4]). The solvent accessible cavities were calculated with the program Caver ([@bib6]).

The multiple sequence alignments were performed using the program Clustal Omega ([@bib33]).

Vesicular zinc uptake assay {#s4-5}
---------------------------

In a previous study, it has been shown that HsZnT8 expressed in HEK293 cells facilitated vesicular Zn^2+^ uptake when Zn^2+^ was introduced into cytosol by permeabilizing surface membrane using a Zn^2+^ ionophore ([@bib25]). In that study, the vesicular Zn^2+^ accumulation was monitored by Zinpyr-1, a membrane-permeable Zn^2+^-selective fluorescent indicator that can be localized in vesicles. We adopted similar cell-based vesicular Zn^2+^ uptake assay in our study, except that we permeabilized the cells with digitonin and directly monitored the cytosolic Zn^2+^ concentration decrease caused by vesicular Zn^2+^ uptake using Zn^2+^ indicator FluoZin-3 as described below. HEK293F cells expressing HsZnT8 were harvested 36 hr after virus infection. To remove residual media and Zn^2+^, the cell pellet from 30 mL suspension culture was washed with 30 mL of uptake buffer (20 mM Hepes pH7.4 125 mM KCl, 5 mM NaCl, 10 mM Glucose, 10 μM Phenanthroline) three times, and then re-suspended in uptake buffer to a final concentration of 15 × 10^6^ cells/mL. The cells were maintained on ice throughout. To measure Zn^2+^ uptake, 100 μL of cell suspension was added into each well of a 96-well plate (Corning) and the following reagents were added sequentially: 1 μM FluoZin-3, 0.01% digitonin, and 9 μM ZnCl~2~. Zinc uptake was monitored by measuring FluoZin-3 fluorescence change for 5 min using a Molecular Devices SpectraMax M3 plate reader (excitation/emission: 490 nm/525 nm).

Western blot analysis was performed on each sample used for uptake assay to ensure protein expression was comparable among the HsZnT8 WT and mutants. Mouse anti-Flag antibodies (Sigma) were used to detect HsZnT8. Mouse anti-β-actin (Santa Cruz Biotechnology) was used as a loading control. HRP-conjugated sheep anti-mouse antibody (GE Healthcare) was used as the secondary antibody. The expression level of HsZnT8 was calculated based on the quantification of the total level of ZnT8 and β-actin from the western blot analysis. All functional data were analyzed in GraphPad Prism 8 (GraphPad Software, Inc) or OriginPro (OriginLab Corp.). To obtain the rate of zinc uptake, the linear phase of the uptake measurement -- the first 30 s of the reaction following zinc addition -- was determined by fitting the data to a linear regression equation in OriginPro 8; the slope of the fit is taken as the rate of zinc uptake. The zinc uptake rates were normalized to the expression level of HsZnT8. Further analysis are indicated in the figure legend.

The identities of all the cell lines have been authenticated. The mycoplasma contamination testing was performed and shown to be negative.

Quantification and statistical analysis {#s4-6}
---------------------------------------

The number of independent experiment, the method used in statistical test, and the statistical significance are indicated in each figure legend and source manuscript files.
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Data availability {#s7}
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The Cryo-EM maps of HsZnT8 determined in three different conditions have been deposited in the Electron Microscopy Data Bank, and the corresponding atomic coordinates have been deposited to the RCSB Protein Data Bank, with the entry ID: EMD-22285 and PDB 6XPD for the structure of HsZnT8-DM, EMD-22286 and PDB 6XPE for the structure of HsZnT8-WT in the presence of zinc, and EMD-22287 and PDB 6XPF for the structure of HsZnT8-WT in the absence of zinc. Source data files have been provided for Figure 2g and 2h.

The following datasets were generated:

XueJXieTZengWJiangYBaiXc2020Cryo-EM structure of human ZnT8 double mutant - D110N and D224N, determined in outward-facing conformationElectron Microscopy Data BankEMD-22285

XueJXieTZengWJiangYBaiXc2020Cryo-EM structure of human ZnT8 WT, in the presence of zinc, determined in outward-facing conformationElectron Microscopy Data BankEMD-22286

XueJXieTZengWJiangYBaiXc2020Cryo-EM structure of human ZnT8 WT, in the absence of zinc, determined in heterogeneous conformations- one subunit in an inward-facing and the other in an outward-facing conformationElectron Microscopy Data BankEMD-22287

XueJXieTZengWJiangYBaiXc2020Cryo-EM structure of human ZnT8 double mutant - D110N and D224N, determined in outward-facing conformationRCSB Protein Data Bank6xpd

XueJXieTZengWJiangYBaiXc2020Cryo-EM structure of human ZnT8 WT, in the presence of zinc, determined in outward-facing conformationRCSB Protein Data Bank6xpe

XueJXieTZengWJiangYBaiXc2020Cryo-EM structure of human ZnT8 WT, in the absence of zinc, determined in heterogeneous conformations- one subunit in an inward-facing and the other in an outward-facing conformationRCSB Protein Data Bank6xpf

The following previously published datasets were used:

LuMChaiJFuD2009Structural basis for the autoregulation of the zinc transporter YiiPElectron Microscopy Data Bank3h90

Lopez-RedondoMLCoudrayNZhangZAlexopoulosJStokesDL2018CryoEM Structure of the Zinc Transporter YiiP from helical crystalsElectron Microscopy Data Bank5vrf
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The authors report several cryo-EM structures of human zinc transporter ZnT8, which uses the transmembrane proton gradient to pump zinc into insulin secretory granules. There, zinc is necessary to pack insulin into secretion-ready hexameric form. The structures push the technical capabilities of cryo-EM because of the comparatively small size of the transporter. They reveal the transport mechanism, the location of mutations associated with increased risk of type 2 diabetes, and the location of the loop that has been proposed to be the target of autoantibodies in type 1 diabetes patients.

**Decision letter after peer review:**

Thank you for submitting your article \"Cryo-EM structures of human ZnT8 in both outward- and inward-facing conformations\" for consideration by *eLife*. Your article has been reviewed by Olga Boudker as the Senior and Reviewing Editor, and two reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Aravind Penmatsa (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

The manuscript reports cryo-EM structures of the dimeric human ZnT8 from the ZIP protein family in the outward-facing conformation at 3.8 Å and inward-facing conformation at a moderate resolution of 5.9 Å. The authors manage to reconstruct the structure of this sub-100kDa (\~70kDa) Zn transporter using the phase plate and the study joins a small but increasing list of integral membrane transporter structures recently elucidated through cryo-EM. The biomedical importance of ZnT8 in insulin secretion, Zn enrichment in secretory granules, and elucidation of different conformations along the transport cycle make this study highly relevant. However, more rigorous data analysis and presentation are required to warrant publication. Below are the points raised by the reviewers that would need to be addressed.

Essential revisions:

1\) The major concern is with the certainty that the authors claim the presence/absence of Zn^2+^, especially since the wild-type structures solved with and without Zn^2+^ are at only \~4 Å and \~6 Å resolutions.

Throughout the entire manuscript and figures, there are no indications of statistical significance for interpreting cryo-EM densities. It is important that the displayed/compared volumes show parts of the map that have a corresponding level of significance. This is especially concerning the presence and absence of the Zn^2+^ ion density (Figure 2). In making direct comparisons between density maps that contain different statistical compositions and distributions it is essential to scale and normalize the maps with respect to the lowest quality map. Then displaying the normalized data and stating a number of sigmas above the mean threshold to which the density is present, would allow for evaluation of the density maps on an equal footing. This should be explicitly stated in Materials and methods section and figure legends should this measure have been carried out. Moreover, a density difference map should be calculated to adequately satisfy the author\'s statements of \'unequivocal\' and \'clear\' presence of Zn^2+^ (subsections "Zn^2+^ binding sites in CTD" and "Zn^2+^ binding sites in TMD"). However, even at \~4 Å and \~6 Å resolutions, there is still a potential for the presence of noise to be misinterpreted as Zn^2+^ density, and I suggest the authors rephrase their strong assertions of modeling ions at this resolution.

2\) Subsection "Structural determination of HsZnT8": building a relatively accurate model at 5.9 Å for the HsZnT8-WT in the absence of Zn^2+^ is quite a bit of a stretch, and side chains cannot accurately be modeled at this resolution. Interpretations should be limited to what one can observe in the density map and leave speculation for the discussion. Moreover, the model for this structure should be deposited as C-α representations, since minimal side-chain densities are observed.

3\) HsZnT8-DM in the absence of Zn^2+^ (Figure 1---figure supplement 2), there appears to be quite a bit of variation in the central TMs (TM6 and TM3) after initial 3D refinement. Some explanation should be provided for this, given that this domain is proposed to be static (subsection "Structural changes from outward- to inward-facing states"). Additionally, were the other classes refined? If so, to what resolutions? Even at 6 Å, as in HsZnT8-WT, some interpretations could expand the understanding of the protein dynamics.

4\) The data is presented in a way that it is very difficult to assess the statement \"the two conformations appear to be energetically equivalent, allowing the transporter to be evenly distributed between the two conformations.\" (See subsection "The mechanism for Zn^2+^/H^+^ antiporting in HsZnT8"). Consider revising or provide more substantial evidence for the energetics and \"even distribution\".

5\) The authors should include additional discussion of what is known about the Zn^2+^ binding affinity for each of the sites and physiologically relevant available Zn^2+^ concentrations? Would the transporters ever see an environment in which there is no Zn^2+^ present?

6\) The authors have proposed that the structures will provide insights into human disease, but fail to follow through on this. Can disease-causing mutations be mapped to the structures generated in this study or homology models created for this purpose? This would elevate your claim and provide substantial advancement in understanding diabetes.

7\) Figure 2 legend should be re-written for clarity as it does not specifically indicate which structure/condition is presented. The threshold for evidence of density should be presented and translated into a number of sigmas above the mean.

8\) Subsection "Overall structure of HsZnT8 in the outward-facing conformation": The statement, \"Notably, clear lipid density is visible in the space between the two TMDs\" should be supported with a figure displaying the densities as well as further discussion on its identity.

9\) In the Zn^2+^ uptake experiments (subsection "Zn^2+^ binding sites in CTD"), it is unclear how the data was normalized. The particulars of the data processing were omitted in the Materials and methods section, directing the reader to the figure legend (subsection "Vesicular zinc uptake assay"), where there is no indication of how data was normalized to protein expression.

10\) Subsection "Structural determination of HsZnT8": The authors state HsZnT8-WT in the absence of Zn^2+^ yielded heterogeneous conformations however, Figure 3---figure supplement 1 does not depict this.

11\) How do the solvent-accessible transport pathways appear as a 3D volume in the inward- and outward-facing structures?

12\) Subsection "Model building, refinement and validation": Is the modeling really de novo if a template from the crystal structure was used? This should be rephrased to better represent the contribution of previous structural information.

13\) Upon examining the coordinates of the three deposited structures it is evident that in the WT HsZnT8 reported without Zinc, the authors model D110 and D224 as asparagines in chain B at site STM. This is a likely modeling error of the authors as it is fairly clear that the authors are reporting HsZnT8 structure without Zinc in the WT state and not as a heterodimer of HsZnT8DM (CH B) and WT HsZnT8 (CH A).

14\) Among the residues involved in the charge interlock (R138; E276) between TMs 3 and 6 there is a break in the symmetry between the residues in the WT ZnT8 structure lacking Zinc. The E276 of chain A is positioned away from forming a salt bridge interaction in the structure. Given the poor resolution of this structure, the side chain density is likely not visible in this case. However, given the lack of any structural changes in the cytosolic domains the authors may correct the orientation of this side chain.

15\) The H106 which should be coordinating with Zn in the WT structure is modeled away from the Zinc. The imidazole ring should be brought closer within the coordinating radius of the STM Zn ion in the WT-Zn bound structure.

16\) The structural comparisons between outward and inward-facing conformations in Figure 3 would be best be represented with the addition of interhelical angles to represent structural transitions particularly between TMs 1, 2, 4 and 5 which undergo substantial changes.

17\) None of the figures showing structural overlaps report C-α RMSD values, be it within ZnT8 structure or the comparison between nZnT8 and EcYiiP/SoYiiP structures. The authors could even consider including a table with domain wise RMSD comparisons between different structures.

18\) Despite drawing an extensive comparison between the EcYiiP and SoYiip with HsZnT8, the MSA in Figure 1---figure supplement 5 does not report structure-based sequence comparison between HsZnT8 vs. the prokaryotic Zn transporters. Having this multiple sequence alignment would help the readers significantly.

19\) The authors do not particularly indicate the concentrations of Zn used in their work. It is not clear from the methods or the text as to what is the concentration of zinc when they say \'presence of Zn\'.

20\) The Zn uptake assay displaying activity is a fairly qualitative one and does not report any kinetic parameters. Would the authors be able to provide KM and Vmax values for the transport and their mutants as part of the revision?

21\) The discussion of the putative Zn-binding site at the luminal face of the transporter as potential \'luminal Zn sensor\' is speculative at best since the earlier citation by Gola et al., 2019, suggests that there is a loss of transport activity upon mutations of E88 and D103. While this suggests that the residues are important for Zn permeation, it does not indicate as to why the site could sense Zn. Also, if the site senses Zn at high concentrations the transport activity is likely to be retained except at high luminal Zn levels. The authors may consider altering this part of the Discussion section.

22\) The dual conformation found in the WT ZnT8 structure in the absence of Zinc is a rather interesting observation. While it is plausible that the transporter has a two-state model without a likely occluded state it would be interesting for the authors to discuss the possibility of the two protomers, transporting Zn, to be decoupled from the dimerization helices and the CTD and transport Zn independent of each other.

23\) The summary figure (Figure 4) can be improved by adding the pH gradients and Zn concentration gradients across the bilayer. The release of Zn inside the secretory granule can be directly depicted as being released from the molecule upon protonation rather than as arrows between two states.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Cryo-EM structures of human ZnT8 in both outward- and inward-facing conformations\" for further consideration by *eLife*. Your revised article has been evaluated by Olga Boudker as Senior and Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

As you will see from the comments below, the reviewers are questioning the assignment of the excess density as a lipid. You should substantiate the assignment and edit the text to reflect uncertainty.

Reviewer \#1:

The authors have carefully addressed the concerns that I had raised in the earlier version and have made changes both to the text and the figures as recommended. The manuscript figures display marked improvement and provide greater clarity to the reader in this version. I do not have any major concerns and the manuscript can be accepted after a couple of minor concerns are addressed.

Reviewer \#2:

The authors have addressed most of the points that were raised in the initial review. I do appreciate the authors\' responses, and new analyses and discussions added to the revised manuscript. However, the manuscript still lacks a satisfactory discussion related to the lipids identified in the in HsZnT8 structure. Specific points are given below and need to be addressed.

\- Subsection "Overall structure of HsZnT8 in the outward-facing conformation": \"Notably, clear lipid density is visible in the space between the two TMDs\". While the authors have provided a new figure displaying anticipated lipid density (Figure 1---figure supplement 3C), it remains unclear why these densities were ascribed to lipid molecules. The data presented does not support the identification of a lipid. There is only a small density, no bulky head group and no continuous density to lipid bilayer boundaries. What evidence do you have to support ascribing density as lipid? This density could be due to image processing artifacts, noise, bound detergent, etc. It would be impactful to provide clarification/discussion on identity of lipid-like densities or remove this supposition from the manuscript.

\- Figure 1A legend -- the authors should indicate a threshold level used to display the EM density map; if the map was filtered for this display, it should be also indicated in the figure legend.

\- Figure 1---figure supplement 3 -- \"Lipid densities....\" -- please provide statistical definition of visualized lipid-like densities. Why these densities were escribed to lipid molecules? It would be impactful to provide some clarification.

\- Figure 1---figure supplement 5 and Figure 1---figure supplement 6. Indicate GI/protein accession numbers for the sequence alignments. Indicate how the multiple alignments were accomplished.

\- Figure 2B,C,D: \"The densities for the Zn^2+^ ion are displayed as blue mesh (6 σ)...\" -- Cryo-EM densities shown as a blue mesh at 6σ include protein as well. Consider revising.

\- Figure 2G and Figure 3C -- The surface-rendered model of the outward-facing (Figure 2) and inward-facing (Figure 3) subunit from the HsZnT8-WT structure obtained in the absence of Zn. It would make better sense to show both conformations side-by-side in the same figure.

\- Figure 3---figure supplement 1B -- The ResMap data could be presented for additional clarity by using an alternate coloring scheme or the same scale as in Figure 1---figure supplement 2.

\- While the % particles in each image processing step used to determine the final map were included as previously requested, the % particles in the discarded maps from 3D classification and 3D refinement will provide additional clarity for data distribution.

\- Indicate if RMSDs are based on C-α or all-atom.

10.7554/eLife.58823.sa2

Author response

> Essential revisions:
>
> 1\) The major concern is with the certainty that the authors claim the presence/absence of Zn^2+^, especially since the wild-type structures solved with and without Zn^2+^ are at only \~4 Å and \~6 Å resolutions.
>
> Throughout the entire manuscript and figures, there are no indications of statistical significance for interpreting cryo-EM densities. It is important that the displayed/compared volumes show parts of the map that have a corresponding level of significance. This is especially concerning the presence and absence of the Zn^2+^ ion density (Figure 2). In making direct comparisons between density maps that contain different statistical compositions and distributions it is essential to scale and normalize the maps with respect to the lowest quality map. Then displaying the normalized data and stating a number of sigmas above the mean threshold to which the density is present, would allow for evaluation of the density maps on an equal footing. This should be explicitly stated in Materials and methods section and figure legends should this measure have been carried out. Moreover, a density difference map should be calculated to adequately satisfy the author\'s statements of \'unequivocal\' and \'clear\' presence of Zn^2+^ (subsections "Zn^2+^ binding sites in CTD" and "Zn^2+^ binding sites in TMD"). However, even at \~4 Å and \~6 Å resolutions, there is still a potential for the presence of noise to be misinterpreted as Zn^2+^ density, and I suggest the authors rephrase their strong assertions of modeling ions at this resolution.

Thank this reviewer for this critical comment. We have normalized the cryo-EM map of HsZnT8-DM at 3.8 Å resolution to the same grey scale as the cryo-EM map of HsZnT8-WT in the presence of Zn^2+^ at 4.1 Å resolution, by using the command "vop scale" in Chimera. We have stated the number of sigmas to which the densities of Zn^2+^ are displayed in the figure legend of Figure 2. In addition, we calculated the density difference between the normalized cryo-EM maps of HsZnT8 in the absence and presence of Zn^2+^. This difference map is presented as orange blobs in Figure 2. Following reviewer's comment, we also removed all the strong assertions, such as "unequivocal", from the text. The detailed approaches for normalizing the cryo-EM map and calculating the difference map are described in the Materials and methods section.

> 2\) Subsection "Structural determination of HsZnT8": building a relatively accurate model at 5.9 Å for the HsZnT8-WT in the absence of Zn^2+^ is quite a bit of a stretch, and side chains cannot accurately be modeled at this resolution. Interpretations should be limited to what one can observe in the density map and leave speculation for the discussion. Moreover, the model for this structure should be deposited as C-α representations, since minimal side-chain densities are observed.

We agree with the reviewer that the side chains of the protein cannot be accurately modeled at this resolution. Therefore, the conformational changes of ZnT8 TMD between outward- to inward-facing states are only depicted and discussed at the secondary structure level throughout the entire manuscript. We have removed all the side-chains from the model of HsZnT8-WT in the absence of Zn^2+^.

> 3\) HsZnT8-DM in the absence of Zn^2+^ (Figure 1---figure supplement 2), there appears to be quite a bit of variation in the central TMs (TM6 and TM3) after initial 3D refinement. Some explanation should be provided for this, given that this domain is proposed to be static (subsection "Structural changes from outward- to inward-facing states"). Additionally, were the other classes refined? If so, to what resolutions? Even at 6 Å, as in HsZnT8-WT, some interpretations could expand the understanding of the protein dynamics.

Thank this reviewer for raising this question. After we align all classes shown in Figure 1---figure supplement 2 together, all the TMs between different classes can be perfectly overlapped with each other (see [Author response image 1](#sa2fig1){ref-type="fig"}), suggesting that there are no conformational variations in TMs among all these classes. It has been well known that the extreme hydrophobic air-water interface on the cryo-EM grids may potentially damage protein complex. It is possible that the particles from other "bad" classes may be damaged more than those selected from this single "good" class, which could explain why the 3D reconstruction for other classes were determined in similar conformations but at lower resolution.

![](elife-58823-resp-fig1){#sa2fig1}

> 4\) The data is presented in a way that it is very difficult to assess the statement \"the two conformations appear to be energetically equivalent, allowing the transporter to be evenly distributed between the two conformations.\" (See subsection "The mechanism for Zn^2+^/H^+^ antiporting in HsZnT8"). Consider revising or provide more substantial evidence for the energetics and \"even distribution\".

Thank this review for the critical comment. Indeed, we don't know for certain that the outward- and inward-facing conformations are energetically equivalent in HsZnT8. We also can't provide more evidence to support this statement. We, therefore, remove this statement from the revised manuscript.

> 5\) The authors should include additional discussion of what is known about the Zn^2+^ binding affinity for each of the sites and physiologically relevant available Zn^2+^ concentrations? Would the transporters ever see an environment in which there is no Zn^2+^ present?

We can't find any literature reporting the Zn^2+^ binding affinities of ZnTs. As there are totally 4 different Zn^2+^ binding sites in each subunit of ZnT8, it would be difficult to measure the Zn^2+^ binding affinity for each site individually.

The free Zn^2+^ concentration in cytosol is between 200 pM to 1.5 nM; whereas the free Zn^2+^ concentration in insulin secretory granule is about 120 nM. Thus, there are always Zn^2+^ present on both cytosolic and luminal sides of ZnT8, although the Zn^2+^ concentration difference between the two sides are more than 100 fold. We have added this information in the revised manuscript.

> 6\) The authors have proposed that the structures will provide insights into human disease, but fail to follow through on this. Can disease-causing mutations be mapped to the structures generated in this study or homology models created for this purpose? This would elevate your claim and provide substantial advancement in understanding diabetes.

We thank the reviewer for the suggestion. We have prepared a new figure supplement (Figure 4---figure supplement 1) to map the disease-associated point mutations of ZnT8 as well as those mutations found in other ZnTs but are conserved in ZnT8 onto the structure.

> 7\) Figure 2 legend should be re-written for clarity as it does not specifically indicate which structure/condition is presented. The threshold for evidence of density should be presented and translated into a number of sigmas above the mean.

We have rewritten the legend of Figure 2 to improve its clarity, and stated the sigma level of the Zn^2+^ density in the legend.

> 8\) Subsection "Overall structure of HsZnT8 in the outward-facing conformation": The statement, \"Notably, clear lipid density is visible in the space between the two TMDs\" should be supported with a figure displaying the densities as well as further discussion on its identity.

We have prepared a new figure supplement (Figure 1---figure supplement 3C) to show the lipid density between the two TMDs.

> 9\) In the Zn^2+^ uptake experiments (subsection "Zn^2+^ binding sites in CTD"), it is unclear how the data was normalized. The particulars of the data processing were omitted in the Materials and methods section, directing the reader to the figure legend (subsection "Vesicular zinc uptake assay"), where there is no indication of how data was normalized to protein expression.

Thank this reviewer for this critical comment. We have repeated all the uptake assays. The results of western blot analysis of HsZnT8 WT and mutants are shown in Figure 2H, indicating the protein expression level in each uptake assay. β-actin was used as the loading control. The relative expression level for each HsZnT8 sample was calculated through the quantification of the western blotting results of HsZnT8 and β-actin, by using ImageJ. Subsequently, the relative uptake rate for each HsZnT8 sample was calculated from the vesicular zinc uptake assay (Figure 2H and more detail in method section). Finally, the uptake rates were normalized to the HsZnT8 expression levels, and are shown in Figure 2I. We have rewritten the legend and method in the revised manuscript.

> 10\) Subsection "Structural determination of HsZnT8": The authors state HsZnT8-WT in the absence of Zn^2+^ yielded heterogeneous conformations however, Figure 3---figure supplement 1 does not depict this.

We have labeled the map in Figure 3---figure supplement 1 to indicate the heterogeneous conformations.

> 11\) How do the solvent-accessible transport pathways appear as a 3D volume in the inward- and outward-facing structures?

As suggested by the reviewer, we have prepared a new figure supplement (Figure 3---figure supplement 3D) to show the transport pathways in both outward- and inward-facing conformations as 3D volumes. The 3D transport pathways are calculated by using program Caver.

> 12\) Subsection "Model building, refinement and validation": Is the modeling really de novo if a template from the crystal structure was used? This should be rephrased to better represent the contribution of previous structural information.

Indeed, we used the structure of EcYiiP as the reference to model HsZnT8. We have rephrased a sentence in the revised manuscript to "allowing us to build a near complete model containing 302 out of 320 residues for each subunit, with the help of the crystal structure of EcYiiP".

> 13\) Upon examining the coordinates of the three deposited structures it is evident that in the WT HsZnT8 reported without Zinc, the authors model D110 and D224 as asparagines in chain B at site STM. This is a likely modeling error of the authors as it is fairly clear that the authors are reporting HsZnT8 structure without Zinc in the WT state and not as a heterodimer of HsZnT8DM (CH B) and WT HsZnT8 (CH A).

We apologize for this error and corrected it in the revised model.

> 14\) Among the residues involved in the charge interlock (R138; E276) between TMs 3 and 6 there is a break in the symmetry between the residues in the WT ZnT8 structure lacking Zinc. The E276 of chain A is positioned away from forming a salt bridge interaction in the structure. Given the poor resolution of this structure, the side chain density is likely not visible in this case. However, given the lack of any structural changes in the cytosolic domains the authors may correct the orientation of this side chain.

As also suggested by another reviewer, we have removed all the side-chains from the model of HsZnT8 in the absence of Zn^2+^ due to the resolution of the structure. This could avoid any misunderstanding of our structures.

> 15\) The H106 which should be coordinating with Zn in the WT structure is modeled away from the Zinc. The imidazole ring should be brought closer within the coordinating radius of the STM Zn ion in the WT-Zn bound structure.

We have adjusted the side-chain rotamer of H106 in the revised model.

> 16\) The structural comparisons between outward and inward-facing conformations in figure 3 would be best be represented with the addition of interhelical angles to represent structural transitions particularly between TMs 1, 2, 4 & 5 which undergo substantial changes.

As suggested, we have prepared a new figure supplement (Figure 3---figure supplement 3A-B) to depict angular variation of each TM between outward- and inward-facing conformations. We also calculated the interhelical angles of each TM between two states. This result was shown in Figure 3---figure supplement 3C.

> 17\) None of the figures showing structural overlaps report C-α RMSD values, be it within ZnT8 structure or the comparison between nZnT8 and EcYiiP/SoYiiP structures. The authors could even consider including a table with domain wise RMSD comparisons between different structures.

As suggested, we have calculated the RMSD for each domain between HsZnT8 and EcYiiP/SoYiiP. These results are shown in Figure 1---figure supplement 4F and Figure 3---figure supplement 2E.

> 18\) Despite drawing an extensive comparison between the EcYiiP and SoYiip with HsZnT8, the MSA in Figure 1---figure supplement 5 does not report structure-based sequence comparison between HsZnT8 vs. the prokaryotic Zn transporters. Having this multiple sequence alignment would help the readers significantly.

We have prepared a new figure supplement (Figure 1---figure supplement 6) to show the multiple sequence alignment between HsZnT8, EcYiiP and SoYiiP.

> 19\) The authors do not particularly indicate the concentrations of Zn used in their work. It is not clear from the methods or the text as to what is the concentration of zinc when they say \'presence of Zn\'.

We have explicitly indicated the Zn^2+^ concentration used in this work in the revised manuscript.

> 20\) The Zn uptake assay displaying activity is a fairly qualitative one and does not report any kinetic parameters. Would the authors be able to provide KM and Vmax values for the transport and their mutants as part of the revision?

The uptake assay used in this study only aims to provide qualitative comparison of the transporter activity between WT and mutants. In our assay, the concentration of contaminated zinc, zinc chelator 1,10-phenanthroline and added zinc are all in the μM range, so we can't calculate the free zinc concentration accurately. This means we cannot use this assay to accurately measure the KM and Vmax.

> 21\) The discussion of the putative Zn-binding site at the luminal face of the transporter as potential \'luminal Zn sensor\' is speculative at best since the earlier citation by Gola et al., 2019, suggests that there is a loss of transport activity upon mutations of E88 and D103. While this suggests that the residues are important for Zn permeation, it does not indicate as to why the site could sense Zn. Also, if the site senses Zn at high concentrations the transport activity is likely to be retained except at high luminal Zn levels. The authors may consider altering this part of the Discussion section.

We agree with this reviewer that the discussion for this putative Zn-binding site is very speculative, and the previously published results on ZnT2 can't support our speculation. We have completely removed this part in the revised manuscript.

> 22\) The dual conformation found in the WT ZnT8 structure in the absence of Zinc is a rather interesting observation. While it is plausible that the transporter has a two-state model without a likely occluded state it would be interesting for the authors to discuss the possibility of the two protomers, transporting Zn, to be decoupled from the dimerization helices and the CTD and transport Zn independent of each other.

We agree with the reviewer and this is actually what we have suggested in the manuscript, which stated: "the Zn^2+^ transport activity of HsZnT8 is unlikely to be coupled between the two subunits within a dimer, allowing each subunit to carry out Zn^2+^ transport activity independently".

> 23\) The summary figure (Figure 4) can be improved by adding the pH gradients and Zn concentration gradients across the bilayer. The release of Zn inside the secretory granule can be directly depicted as being released from the molecule upon protonation rather than as arrows between two states.

We have revised Figure 4, as suggested.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Reviewer \#2:
>
> The authors have addressed most of the points that were raised in the initial review. I do appreciate the authors\' responses, and new analyses and discussions added to the revised manuscript. However, the manuscript still lacks a satisfactory discussion related to the lipids identified in the in HsZnT8 structure. Specific points are given below and need to be addressed.
>
> \- Subsection "Overall structure of HsZnT8 in the outward-facing conformation": \"Notably, clear lipid density is visible in the space between the two TMDs\". While the authors have provided a new figure displaying anticipated lipid density (Figure 1---figure supplement 3C), it remains unclear why these densities were ascribed to lipid molecules. The data presented does not support the identification of a lipid. There is only a small density, no bulky head group and no continuous density to lipid bilayer boundaries. What evidence do you have to support ascribing density as lipid? This density could be due to image processing artifacts, noise, bound detergent, etc. It would be impactful to provide clarification/discussion on identity of lipid-like densities or remove this supposition from the manuscript.

Thanks to this reviewer for the critical comment. We agree with this reviewer that these two density blobs, shown in Figure 1---figure supplement 3C, could be lipid, detergent, or even noise. Due to the uncertainty in assigning this density, we have completely removed this supposition and Figure 1---figure supplement 3C in the revised manuscript.

> \- Figure 1A legend -- the authors should indicate a threshold level used to display the EM density map; if the map was filtered for this display, it should be also indicated in the figure legend.

We have added the map threshold level in the legend of Figure 1A, as suggested.

> \- Figure 1---figure supplements 3 -- \"Lipid densities....\" -- please provide statistical definition of visualized lipid-like densities. Why these densities were escribed to lipid molecules? It would be impactful to provide some clarification.

We have removed the discussion of this unidentified density as well as Figure 1---figure supplement 3C in the revised manuscript.

> \- Figure 1---figure supplement 5 and Figure 1---figure supplement 6. Indicate GI/protein accession numbers for the sequence alignments. Indicate how the multiple alignments were accomplished.

As suggested, we have added the protein accession numbers in the legends of Figure 1---figure supplement 5 and Figure 1---figure supplement 6. The multiple sequence alignments were calculated by Clustal Omega. We have indicated this in the Materials and methods section, and cited the original publication of Clustal Omega.

> \- Figure 2B,C,D: \"The densities for the Zn^2+^ ion are displayed as blue mesh (6 σ)...\" -- Cryo-EM densities shown as a blue mesh at 6σ include protein as well. Consider revising.

We have rewritten this sentence to "The cryo-EM densities are displayed as blue mesh (6 σ).".

> \- Figure 2G and Figure 3C -- The surface-rendered model of the outward-facing (Figure 2) and inward-facing (Figure 3) subunit from the HsZnT8-WT structure obtained in the absence of Zn. It would make better sense to show both conformations side-by-side in the same figure.

As suggested, we have shown surface-rendered models for both outward and inward conformations side-by-side in Figure 3C.

> \- Figure 3---figure supplement 1B. The ResMap data could be presented for additional clarity by using an alternate coloring scheme or the same scale as in Figure 1---figure supplement 2.

We have changed the coloring scheme for the local resolution distribution result in Figure 3---figure supplement 1B.

> \- While the % particles in each image processing step used to determine the final map were included as previously requested, the % particles in the discarded maps from 3D classification and 3D refinement will provide additional clarity for data distribution.

We have added the % particles for all the 3D classes.

> \- Indicate if RMSDs are based on C-α or all-atom.

The RMSDs were calculated based on C-α atom only. We have indicated this in the figure legend.
